NCT05173415 (MALLORCA) is a NA clinical trial of Sirius Pintution in Breast Cancer, sponsored by Constanze Elfgen.

Who is sponsoring NCT05173415?

NCT05173415 is sponsored by Constanze Elfgen.

What drugs are being tested in NCT05173415?

Interventions in NCT05173415: Sirius Pintution, HydroMARK (C) Clip.

What condition does NCT05173415 study?

NCT05173415 studies Breast Cancer.

Is NCT05173415 still recruiting?

NCT05173415 is currently completed. Last updated 24 February 2025.

Last reviewed 2025-02-24 · How we verify

NCT05173415: MALLORCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Marker Technique Comparison in Targeted Axillary Dissection

Completed NA Last updated 24 February 2025

What this trial tests

NA trial testing Sirius Pintution in Breast Cancer in 40 participants. Completed in 31 January 2025.

Timeline

1 August 2023

Primary endpoint
31 January 2025

31 January 2025

Quick facts

Lead sponsor	Constanze Elfgen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	1 August 2023
Primary completion	31 January 2025
Estimated completion	31 January 2025
Sites	4 locations across Switzerland

Drugs / interventions tested

Sirius Pintution
HydroMARK (C) Clip

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Constanze Elfgen

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of two methods (Magnetic Marker and standard metal clip) used for localisation and extraction of lymph nodes in Targeted Axillary Dissection (TAD) in patients with breast cancer.This Project will investigate and compare the duration of intervention, detection rate and safety. The participants will be randomized into two groups of equal size.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05173415 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Constanze Elfgen
Last refreshed: 24 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05173415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing